1 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Pinotbio, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma NTX-301, Platinum-based Chemotherapy, Temozolomide - Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Xennials Therapeutics Australia Pty Ltd | 12 | 2021-08-25 | 2022-12-20 |
| Safety and Tolerability of NTX-101 in Korean Healthy Volunteers NTX-101, Placebo - Healthy Volunteers | Phase 1 | Completed | Pinotbio, Inc. | 36 | 2021-03-02 | 2022-04-20 |
Eye Diseases (1) · Glaucoma (1) · Glioma (1) · Optic Neuropathy, Ischemic (1) · Ovarian Neoplasms (1) · Urinary Bladder Neoplasms (1)
Carboplatin (1) · Cisplatin (1) · Platinum Compounds (1) · Temozolomide (1)
Australia (1) · South Korea (1)